Mass spectrometry of doping preparations of a new generation: Peroxisome proliferator-activated receptor agonists

2010 ◽  
Vol 65 (13) ◽  
pp. 1411-1419
Author(s):  
M. A. Dikunets ◽  
E. D. Virus ◽  
E. N. Semenistaya ◽  
T. G. Sobolevsky ◽  
G. M. Rodchenkov
2007 ◽  
Vol 21 (9) ◽  
pp. 2136-2151 ◽  
Author(s):  
Yueying Zhen ◽  
Kristopher W. Krausz ◽  
Chi Chen ◽  
Jeffrey R. Idle ◽  
Frank J. Gonzalez

Abstract Peroxisome proliferator-activated receptor α (PPARα) is a nuclear receptor with manifold effects on intermediary metabolism. To define a set of urinary biomarkers that could be used to determine the efficacy of PPARα agonists, a metabolomic investigation was undertaken in wild-type and Pparα-null mice fed for 2 wk either a regular diet or a diet containing the PPARα ligand Wy-14,643 ([4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio] acetic acid), and their urine was analyzed by ultra-performance liquid chromatography coupled with time-of-flight mass spectrometry. Principal components analysis of 6393 accurate mass positive ions revealed clustering as a single phenotype of the treated and untreated Pparα (−/−) mice plus two additional discrete phenotypes for the treated and untreated Pparα (+/+) mice. Biomarkers of PPARα activation were identified from their accurate masses and confirmed by tandem mass spectrometry of authentic compounds. Biomarkers were quantitated from raw chromatographic data using appropriate calibration curves. PPARα urinary biomarkers highly statistically significantly elevated by Wy-14,643 treatment included 11β-hydroxy-3,20-dioxopregn-4-en-21-oic acid (>3700-fold), 11β,20-dihydroxy-3-oxopregn-4-en-21-oic acid (50-fold), nicotinamide (>2-fold), nicotinamide 1-oxide (5-fold), 1-methylnicotinamide (1.5-fold), hippuric acid (2-fold), and 2,8-dihydroxyquinoline-β-d-glucuronide (3-fold). PPARα urinary biomarkers highly statistically significantly attenuated by Wy-14,643 treatment included xanthurenic acid (1.3-fold), hexanoylglycine (20-fold), phenylpropionylglycine (4-fold), and cinnamoylglycine (9-fold). These biomarkers arise from PPARα effects on tryptophan, corticosterone, and fatty acid metabolism and on glucuronidation. This study underscores the power of mass spectrometry-based metabolomics combined with genetically modified mice in the definition of monogenic metabolic phenotypes.


FEBS Journal ◽  
2007 ◽  
Vol 274 (23) ◽  
pp. 6094-6105 ◽  
Author(s):  
Karine Hellemans ◽  
Karen Kerckhofs ◽  
Jean-Claude Hannaert ◽  
Geert Martens ◽  
Paul Van Veldhoven ◽  
...  

2017 ◽  
Vol 1 (6) ◽  
pp. 524-537 ◽  
Author(s):  
Guillaume Wettstein ◽  
Jean-Michel Luccarini ◽  
Laurence Poekes ◽  
Patrick Faye ◽  
Francine Kupkowski ◽  
...  

Immunology ◽  
2014 ◽  
Vol 142 (3) ◽  
pp. 484-491 ◽  
Author(s):  
Steven G. Smith ◽  
Mike Hill ◽  
John-Paul Oliveria ◽  
Brittany M. Watson ◽  
Adrian J. Baatjes ◽  
...  

PPAR Research ◽  
2017 ◽  
Vol 2017 ◽  
pp. 1-13 ◽  
Author(s):  
Yadan Chen ◽  
Haiming Ma ◽  
Dasheng Zhu ◽  
Guowei Zhao ◽  
Lili Wang ◽  
...  

Insulin resistance is the undisputed root cause of type 2 diabetes mellitus (T2DM). There is currently an unmet demand for safe and effective insulin sensitizers, owing to the restricted prescription or removal from market of certain approved insulin sensitizers, such as thiazolidinediones (TZDs), because of safety concerns. Effective insulin sensitizers without TZD-like side effects will therefore be invaluable to diabetic patients. The specific focus on peroxisome proliferator-activated receptorγ- (PPARγ-) based agents in the past decades may have impeded the search for novel and safer insulin sensitizers. This review discusses possible directions and promising strategies for future research and development of novel insulin sensitizers and describes the potential targets of these agents. Direct PPARγagonists, selective PPARγmodulators (sPPARγMs), PPARγ-sparing compounds (including ligands of the mitochondrial target of TZDs), agents that target the downstream effectors of PPARγ, along with agents, such as heat shock protein (HSP) inducers, 5′-adenosine monophosphate-activated protein kinase (AMPK) activators, 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) selective inhibitors, biguanides, and chloroquines, which may be safer than traditional TZDs, have been described. This minireview thus aims to provide fresh perspectives for the development of a new generation of safe insulin sensitizers.


Sign in / Sign up

Export Citation Format

Share Document